BridgeBio Pharma CEO Kumar sells $4.38 million in BBIO stock

BridgeBio Pharma's CEO, Kumar, has sold $4.38 million worth of BBIO stock, raising concerns among investors about the company's future. Such significant stock sales by executives can often signal a lack of confidence in the company's performance, leading to speculation and potential volatility in the stock price. This move is particularly noteworthy as it comes at a time when the biotech sector is facing various challenges, making it crucial for stakeholders to closely monitor the company's next steps.